Developer of biosafety technology-based products designed to reduce the damage each one of the viruses causes to health
Developer of biosafety technology-based products designed to reduce the damage each one of the viruses causes to health and the health of the economy.
Other Hardware📍 San Francisco, CAFounded 2020
Current Valuation
$504.5M
as of 2022-Q2
PRIVATE
QL Price
$504.5M
0% vs last round
QuantLogix's current estimate for R-Zero, published 2026-09-27 — in line with the last disclosed round of $504.5M (2022-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$504.5M
2022-Q2
weight 0.05
How this price has held up
No round has priced for R-Zero since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, R-Zero, 2026-09-27 (57c6439f0e7c1090).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is R-Zero going public?
No. R-Zero is private and has not filed to go public. There is no S-1 on file.
What is R-Zero's valuation in 2026?
R-Zero is valued at $504.5M as of 2022-Q2, set by its Series C ($104.5M, May 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has R-Zero filed an S-1?
No public S-1 is on file for R-Zero.
How much has R-Zero raised?
R-Zero has raised $172.2M in total, most recently a Series C of $104.5M in May 2022.
Is R-Zero publicly traded — can you buy R-Zero stock?
No. R-Zero is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for R-Zero on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2020
HQ
San Francisco, CA
Employees
68
Total Raised
$172.2M
Last Round
Series C — $104.5M (May 2022)
IPO Status
private
Fundraising Status
Series C · $104.5M · 4y 4mo ago
privateTotal raised $172.2M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$104.5M
May 2022
—
$504.5M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for R-Zero — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
1
via greenhouse
Product-build share
0%
engineering, research, product, design
Trajectory
steady
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 1 open roles are sales).
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Sr. Solutions Engineer
Counted from R-Zero's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyHardwareInternet of ThingsSmart BuildingSoftwareSustainability
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q2. Refreshed quarterly.